share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Hirawat Samit

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities

施貴寶 | 4：持股變動聲明
SEC announcement ·  03/12 20:44
Moomoo AI 已提取核心訊息
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
On March 10, 2024, Samit Hirawat, EVP, Chief Medical Officer, and Head of Drug Development at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hirawat acquired a total of 38,388 shares through the exercise of derivative securities at no cost. Concurrently, he disposed of 25,354 shares. The disposals included shares used to cover exercise prices or tax liabilities, with some transactions priced at $53.79 per share, resulting in a total market value of $734,179.71. Following these transactions, Hirawat's direct holdings in Bristol-Myers Squibb common stock amounted to 60,279 shares.
2024年3月10日，百時美施貴寶（BMY）執行副總裁、首席醫學官兼藥物開發主管薩米特·希拉瓦特完成了一系列涉及該公司普通股的交易。Hirawat通過免費行使衍生證券，共收購了38,388股股票。同時，他出售了25,354股股票。出售的股票包括用於支付行使價或納稅義務的股票，部分交易定價爲每股53.79美元，總市值爲734,179.71美元。這些交易之後，Hirawat直接持有的百時美施貴寶普通股爲60,279股。
2024年3月10日，百時美施貴寶（BMY）執行副總裁、首席醫學官兼藥物開發主管薩米特·希拉瓦特完成了一系列涉及該公司普通股的交易。Hirawat通過免費行使衍生證券，共收購了38,388股股票。同時，他出售了25,354股股票。出售的股票包括用於支付行使價或納稅義務的股票，部分交易定價爲每股53.79美元，總市值爲734,179.71美元。這些交易之後，Hirawat直接持有的百時美施貴寶普通股爲60,279股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息